# Oral Formulation of Insulin for Preterm Infants

> **NCT01093638** · PHASE2 · TERMINATED · sponsor: **Elgan Pharma Ltd.** · enrollment: 33 (actual)

## Conditions studied

- Premature Birth of Newborn

## Interventions

- **BIOLOGICAL:** Oral Formulation of Insulin
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01093638
- **Lead sponsor:** Elgan Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-08
- **Primary completion:** 2013-08
- **Final completion:** 2016-01
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2021-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01093638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01093638, "Oral Formulation of Insulin for Preterm Infants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01093638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*